BONESUPPORT (Q2 Review): Several catalysts before the next report - Redeye
Bildkälla: Stockfoto

BONESUPPORT (Q2 Review): Several catalysts before the next report - Redeye

The market focused on the revised 2026 sales growth target rather than another quarter of improving profitability and 40% CER sales growth for US CERAMENT G. While confidence has clearly taken a hit, we argue that the long-term investment case remains intact.

The market focused on the revised 2026 sales growth target rather than another quarter of improving profitability and 40% CER sales growth for US CERAMENT G. While confidence has clearly taken a hit, we argue that the long-term investment case remains intact.
Börsvärldens nyhetsbrev